research Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with Baricitinib.
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
Search
for
Sort by
Research
180-210 / 1000+ results research Comparative safety profiles of baricitinib and tofacitinib in the treatment of adult alopecia areata: a pharmacovigilance study based on the FAERS database
Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.
research Calcipotriol/dithranol
research 3,3-Diphenylpentane skeleton as a steroid skeleton substitute: Novel inhibitors of human 5α-reductase 1
A new compound effectively inhibits human 5α-reductase 1.
research Prodrugs of butyric acid from bench to bedside: Synthetic design, mechanisms of action, and clinical applications
New butyric acid prodrugs show promise for cancer treatment, anemia management, and protecting hair from chemotherapy damage.
research Effectiveness of Baricitinib for Nasal, Genital, and Beard Hair Regrowth in Patients with Severe Alopecia Areata: 12-Month Outcomes from a Prospective Observational Study
Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
research Effects of diphencyprone on expression of Bcl-2 protein in patients with Alopecia areata
Diphencyprone increases Bcl-2 protein in patients with hair regrowth from alopecia areata.
research Retraction Note: The gastro protective effects of Cibotium barometz hair on ethanol-induced gastric ulcer in sprague-dawley rats
The article on the stomach-protecting effects of Cibotium barometz hair was retracted due to unreliable data.
research Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response
Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
research Clinical Efficacy and Safety of Baricitinib in Patients With Alopecia Areata in Korea
Baricitinib is effective and safe for treating alopecia areata in Korea.
research Efficacy of baricitinib in treatment of coexisting alopecia areata and lichen planopilaris
Baricitinib effectively treated hair loss and inflammation in a patient with alopecia areata and lichen planopilaris.
research Rational Design and Synthesis of 4-((1R,2R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a Novel, Nonsteroidal Androgen Receptor Antagonist Devoid of Phototoxicity for Dermatological Indications
PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
research Review of efficacy of baricitinib in the treatment of alopecia areata
Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
research Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective
Adding baricitinib will increase costs but offers more treatment options for alopecia areata.
research Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
research The Bis(1,2,3,4-tetrahydroisoquinoline) Alkaloids Cepharanthine and Berbamine Are Ligands of SK Channels
Cepharanthine and berbamine may affect SK channels, influencing their therapeutic effects.
research Baricitinib-Loaded Separable Microneedle Array Patch (S-Map) Based on Hyaluronic Acid for Alopecia Areata Therapy
The patch effectively promotes hair growth for alopecia areata without pain.
research EE325 Budget Impact of Baricitinib for Patients with Severe Alopecia Areata
Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
research There are early, gradual and late responders for scalp hair regrowth in patients with alopecia areata treated with baricitinib
Different people with severe hair loss respond to baricitinib treatment at different times, with some showing improvement early, some gradually, and others later.
research 139 Anti-BCC efficacy of a topical hedgehog inhibitor without adverse effects in BCNS patients in a phase 2 randomized controlled trial
Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.
research Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata
Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.
research Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors and baricitinib: A case report and literature review
A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
![Patent Evaluation: Hexahydrobenzo[f]quinolines as 5α-Reductase Inhibitors](/images/research/1634373b-f615-46c7-a157-21394e3366be/small/21095.jpg)
research Patent Evaluation: Hexahydrobenzo[f]quinolines as 5α-reductase inhibitors
Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.
research Betulinic acid exerts anti‐hepatitis C virus activity via the suppression of NF ‐κB‐ and MAPK ‐ERK 1/2‐mediated COX ‐2 expression
Betulinic acid can help treat hepatitis C by stopping virus replication.
research Effect of baricitinib in patients with alopecia areata: Usefulness of trichoscopic evaluation
research Unexpected Extensive Hair Whitening Following Baricitinib Treatment for Alopecia Universalis: A Case Report and Mechanistic Insights
Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.
research Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: A Real‐World Cohort Study
Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.
research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
research Proteomic Predictors of Baricitinib Response in Severe Alopecia Areata: CCL11 Flags a Refractory Phenotype
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
research Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
Baricitinib was effective in treating a patient with dermatomyositis and hair loss.